Ean Moderator: Anja Sander (Vienna, Austria)

Guest: Peter Dedeken (Sint-Katelijne-Waver, Belgium)

Guest: Vanessa Carvalho (Lisbon, Portugal)

This week we are happy to share an episode about the EAN Leadership Programme. EAN Executive Director, Anja Sander, hosts two participants of the current round of the Leadership Programme: Peter Dedeken and Vanessa Carvalho. They share their motivation, learnings and benefits of participating in the programme, not only for leading others, buts also for leading themselves. The application for the next round of the Leadership Programme opens on 2 December 2024 - please find all information about the application procedure here: EAN Leadership Programme - ean.org

For more insights into the programme, see this article from another participant, Raphael Wurm: Why I applied for the EAN Leadership Programme and what I have learned - eanpages
The link to the mentioned burnout study can be found here: Education Research: Impact of Burnout on Neurology Residents and Research Fellows in Europe | Neurology Education

eanCast Listener Feedback Survey: https://www.surveymonkey.com/r/eanCast

Moderator: Bernhard J. Steinhoff (Kehl-Kork, Germany)

Guest: Jakob Christensen (Aarhus, Denmark)

In this last November episode Bernhard Steinhoff and Jakob Christensen give an update on new data concerning the risk of the offspring of male patients under antiseizure medications. They discuss that the warnings of the EMA about autism spectrum disorders and cognitive impairment that raised major concern now appear less intimidating due to recently published results from a huge Scandinavian registry study.

Moderator: Bernhard J. Steinhoff (Kehl-Kork, Germany)

Guest: Jakob Christensen (Aarhus, Denmark)

This week Bernhard Steinhoff talks with Jakob Christensen about the latest news on the risk of antiseizure medications in pregnancy and beyond. They mention new data on teratogenicity and the increased probability of autism spectrum disorders and cognitive impairment of the offspring.

Moderator: Bernhard J. Steinhoff (Kehl-Kork, Germany)

Guest: Kristl Vonck (Gent, Belgium)

In this episode, Bernhard Steinhoff speaks with expert Kristl Vonck on the latest advancements in neurostimulation therapies for epilepsy. They explore how innovations in vagus nerve and deep brain stimulation are enhancing personalized treatment approaches, offering new hope for epilepsy patients resistant to traditional therapies.

Moderator: Bernhard J. Steinhoff (Kehl-Kork, Germany)

Guest: Andreas Schulze-Bonhage (Freiburg, Germany)

In this episode Bernhard J. Steinhoff and Andreas Schulze-Bonhage discuss the new fascinating perspectives and possibilities of EEG technologies that allow high-class long and ultra-long recordings. Schulze-Bonhage shares these new developments of a method still uniquely important for epileptologists.

Moderator: Theodoros M. Mavridis (Dublin, Ireland)

Guest: Messoud Ashina (Glostrup, Denmark)

In this episode Theodoros M. Mavridis and Messoud Ashina delve into the findings of the Phase 2 HOPE clinical trial, which assesses the efficacy and safety of Lu AG09222, a monoclonal antibody that targets the PACAP pathway. They explore the potential of this innovative treatment for migraine prevention while highlighting the critical role of the PACAP pathway in migraine pathophysiology.

Moderator: Roland Wiest (Bern, Switzerland)

Guest: Randolf Klingebiel (Bielefeld, Germany)

In this episode, Roland Wiest and Randolf Klingebiel explore rare causes of myelopathy, a challenging condition due to its infrequent occurrence and diverse origins. They discuss the diagnostic workup, imaging protocols, and differential diagnoses, emphasizing the importance of collaboration between neurologists and neuroradiologists in managing these complex cases.

Moderator: Raphael Wurm (Vienna, Austria)

Guest: Majda Thurnher (Vienna, Austria)

For this episode, Raphaela Wurm welcomes Majda Thurnher to dive into the challenges and joys of diagnosing spinal cord ischemia as theyexplore MRI protocols, key imaging findings, and the impact of diffusion-weighted imaging.